secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2022-10-31T23:59:59+00:00
Accession:  0001213900-22-067378
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actinium's Iomab-B meets primary endpoint in Phase 3 SIERRA AML trial (p<0.0001)
--------------------------------------------------------------------------------

- Phase 3 SIERRA trial of Iomab-B in AML patients 55+ with active relapsed/refractory disease met primary endpoint of durable complete remission (dCR) at 6 months with p<0.0001.
- Iomab-B is a targeted radiotherapy conditioning regimen prior to bone marrow transplant; compared to conventional care with intent to transplant.
- Company to submit Biologics License Application (BLA) to FDA for approval of Iomab-B; additional SIERRA data expected by year-end 2022.
- CEO Sandesh Seth calls it a significant milestone; CMO Avinash Desai highlights statistical significance and increased access to BMT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390022067378/0001213900-22-067378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390022067378/ea167769-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-067378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer